1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2) (LPAAT-beta)

1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2), also known as cytokine-activated lysophosphatidic acid acyltransferase (LPAAT-beta), is an integral membrane enzyme that catalyzes the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (PA) [1, 3]. While it is a key player in the de novo synthesis of glycerophospholipids and triglycerides, its activity is specifically induced by pro-inflammatory cytokines such as TNF-alpha and IL-1 beta [2]. In response to these stimuli, the PA produced by LPAAT-beta acts as a critical second messenger that amplifies inflammatory signaling, leading to the production of further cytokines and reactive oxygen species [2, 3]. This specific cytokine-activated role makes the enzyme a therapeutic target for conditions characterized by hyper-inflammation, such as sepsis and acute lung injury [2]. Drugs like lisofylline (CT-1501R) were developed to selectively inhibit this pathway to reduce systemic inflammation [2]. However, the enzyme's essential role in lipid storage is highlighted by the fact that loss-of-function mutations in the AGPAT2 gene result in Berardinelli-Seip congenital lipodystrophy type 1 [4]. Consequently, therapeutic modulation must balance anti-inflammatory benefits against potential metabolic disruptions [1, 4].

Other names

Cytokine-activated lysophosphatidic acid acyltransferaseAGPAT21-AGP acyltransferase 2Lysophosphatidic acid acyltransferase beta1-acyl-sn-glycerol-3-phosphate O-acyltransferase 2

Inhibition of the enzymatic conversion of lysophosphatidic acid to phosphatidic acid, thereby blocking a key second messenger pathway in cytokine-mediated inflammatory responses [2].